This e-learning course discusses current and future treatment of unresectable HCC and how to select patients for combination immunotherapy treatment

  • Combination therapy for unresectable or advanced HCC patients, covering both approved therapies and those that are in clinical development.
  • Defining the HCC patient population who should benefit most from each available treatment option based on efficacy and safety profiles.
  • Guidance on treatment sequencing.

This course has been accredited by EACCME® for 1 ECMEC® (as detailed within the Introduction and Objectives below).